



Interim report

1 january - 31 december 2022

Prolight 
Diagnostics

Table of Contents

Financial overview fourth quarter 2022 Group.....	3
Financial overview fourth quarter 2022 Parent company.....	3
Significant events during and after the quarter	4
Financial calendar.....	4
CEO comment	6
Safe point-of-care tests enable faster diagnoses.....	8
Vision.....	8
Strategy.....	9
Point-of-Care – an expanding global market.....	9
Cutting-edge technology.....	10
Prolight has a strong patent portfolio.....	11
Owners.....	12
Group's development during quarter 4 2022.....	13
Group's development during 1 Mar to 31 Dec 2022.....	14
Parent company's development during 1 Oct – 31 Dec 2022	15
Parent company's development during 1 Jan – 31 Dec 2022	16
Other information.....	17
Income Statement, summary Group	18
Balance Sheet, summary Group.....	19
Changes in shareholders equity, Group.....	20
Cash flow from operating activities	21
Income Statement, summary.....	22
Balance Sheet, summary	23
Changes in shareholders equity.....	24
Cash flow statement.....	25
Key ratios	26
Contact	27



Fourth quarter Q4 2022 Group

Formed March 1, 2022

- Net sales amounted to 0.
- Other operating income amounted to kSEK 2,050.
- The profit after tax amounted to kSEK -2,809
- Earnings per share before and after dilution: SEK -0.01.
- Cash flow from current operations was kSEK -5,436
- Cash and cash equivalents amounted to kSEK 54,111 as of December 31, 2022.

Fourth quarter Q4 2022 Parent company

- Net sales amounted to 0 (0).
- Other operating income amounted to kSEK 3,429 (29).
- The profit after tax amounted to kSEK -21,242 (-1,315).
- Earnings per share before and after dilution: -0.09 (-0.01) SEK.
- Cash flow from current operations was kSEK -13,627 (-1,534).
- Cash and cash equivalents amounted to kSEK 45,551 (43,886) as of December 31, 2022.
- The Board proposes that no dividend will be paid for the financial year 2022.

Significant events during the quarter

- Prolight Diagnostics (Prolight) announced that Psyros Diagnostics' (Psyros) highly sensitive digital immunoassay platform can detect extremely low levels of specific proteins. These reproducible proof-of-performance results with Thyroid Stimulating Hormone (TSH) are a crucial step towards developing a highly sensitive assay for the detection of the cardio-specific protein troponin to rule in or rule out myocardial infarction.
- Prolight signed a commercialisation agreement for the PLD MicroFlex POC platform with The Technology Partnership (TTP), in Cambridge, UK, to continue the development and pursue ongoing external initiatives and discussions. Under this agreement, remuneration to Prolight will be paid as future revenues are generated.
- Prolight issued new shares in a set-off issue to its UK partner, The Technology Partnership (TTP). The issue was made as payment for TTP's claim on Prolight for the development project in distributed testing that was announced on 16 December 2021.
- Prolight hired Karl Bullen as Head of Manufacturing in the subsidiary Psyros to ensure its internal manufacturing competence.

Significant events after the end of the quarter

- Prolight's subsidiary Psyros achieved all milestones for the second phase of the SBRI Healthcare grant, primarily by producing functional prototypes for the company's unique digital immunoassay.
- Prolight's subsidiary Psyros chose Integrated Technologies Limited (ITL) to design and develop the commercial instrument for the digital immunoassay, which will be based on the existing functional prototypes. This next step in product development is based on the prototypes internally developed at the subsidiary Psyros.
- Prolight announced that the development project in distributed testing reached a positive milestone with the transfer of two laboratory-based diagnostic tests to the platform. The test results from the project indicate that commercially available laboratory tests can be transferred to the PLD MicroFlex POC platform.

Financial calendar

20 April 2023
Annual Report 2022

11 May 2023
Interim Report Q1

11 May 2023
Annual general meeting

29 August 2023
Interim Report Q2

23 November 2023
Interim Report Q3

21 February 2024
Year end Report

Significant events during the first quarter

- Prolight signed an agreement to acquire the UK company Psyros Diagnostics Ltd at a value of MSEK 65 (about MGBP 5.25). Psyros has developed a POC technology for digital immunoassay, where individual molecules can be counted digitally from a drop of blood.
- Prolight decided on a rights issue of units for approximately MSEK 77, subject to approval by an Extraordinary General Meeting. The issue was secured up to approximately 80 percent by a guarantee consortium syndicated by G&W Fondkommission.
- Prolight acquired the shares of Psyros on 1 March 2022, through an issue in kind.
- Prolight carried out a rights issue that provided the Company with approximately MSEK 62 before issue costs.

Significant events during the second quarter

- Prolight's subsidiary, Psyros, filed a further patent application regarding the Company's unique POC technology to digitally count individual molecules. The patent application involves a refined measurement of individual molecules and was filed with the Intellectual Property Office in the UK.
- Tobias Volker assumed the role of acting subsidiary manager at Psyros. Henrik Ljung became CFO of the Group. Both will be part of the management team and report to CEO Ulf Bladin.
- Prolight's Annual General Meeting was held on 20 May 2022. Masoud Khayyami, Maria Holmlund, and Ulf Bladin were re-elected as board members. Steve Ross, Aileen McGettrick, and Tobias Volker were elected as new board members. Masoud Khayyami was elected as new Chairman of the Board.

Significant events during the third quarter

- Prolight strengthened the organisation by making important new recruitments, partly for the development of the platform and partly by appointing a Head of QA/RA, Andrew Goode-nough, who will lead the implementation of the safety and quality management system and the regulatory work. In addition, Karl Bullen was hired as Head of Manufacturing to ensure Psyros' internal manufacturing competence. Karl Bullen took office on 31 October.
- An Extraordinary General Meeting for Prolight was held on 4 August 2022 and resolved to implement long-term incentive schemes for senior executives and board member Maria Holmlund.

CEO comment

“The next important milestone is proof-of-performance for troponin, which we hope to demonstrate before the summer.

Our digital immunoassay POC system is currently being developed at a very fast pace in our UK subsidiary Psyros. The patent-pending digital immunoassay, where every molecule is counted, enables biomarkers to be detected at extremely low concentrations with high sensitivity and precision. We now have a highly motivated and competent team that has developed six functional instrument prototypes in a very short time. The team strongly believes that this new, ground-breaking POC platform will significantly benefit patients and the rapidly growing market for near-patient testing.

During the quarter, we received reproducible results from a proof-of-performance study confirming that our highly sensitive, digital immunoassay can detect exceedingly low levels of a specific protein, Thyroid Stimulating Hormone (TSH), in human plasma. These low measured concentration levels are, in turn, within the range required to detect and rule out a myocardial infarction with high-sensitivity troponin under current guidelines[1]. These results are an important milestone and bode well for the further development of a high-sensitivity assay for digital detection of troponin, but also for the development of further clinical tests in other major indication areas. The next important milestone is proof-of-performance, specifically for troponin, which we are working intensively to demonstrate before summer 2023.

After the end of the quarter, we were pleased to announce that we had met or exceeded all milestones for the second phase of the SBRI Healthcare grant, primarily by producing functional prototypes of the instrument. Psyros received the grant of around £1 million last year, conditional on achieving certain milestones this year. The grant has accelerated the development of our unique digital immunoassay.

To further accelerate the development, we have

[1] European Cardiology Society's Guidelines on Fourth Universal Definition of Myocardial infarction.



signed an agreement with a subcontractor for the industrialisation of the device. In parallel, our ambition is to set up the first parts of a development production line for cartridge manufacturing on our own premises.

Development work is proceeding according to plan, and we focus on further developing the unique digital technology, including additional data generation and advancement of our prototype system for instruments and cartridge. To raise awareness of our digital immunoassay concept, we aim to showcase it in July 2023 at the American Association for Clinical Chemistry (AACC) international congress, which is considered one of the largest among industry experts.

After the end of the quarter, we were pleased to announce that our technology and development partner, The Technology Partnership (TTP), reached a positive milestone in the development project in distributed testing for the PLD MicroFlex POC platform, with the transfer of two laboratory-based diagnostic tests to the platform. The development project is the first step in demonstrating that the platform can be adapted for existing tests currently implemented in central laboratories without making significant chemical changes. TTP is now working on identifying a suitable commercial partner to take the technology to market. During

the quarter, we signed a commercialisation agreement with TTP for the PLD MicroFlex POC platform to continue development and pursue ongoing external initiatives and discussions. Under this agreement, remuneration to Prolight will be paid as future revenues are generated. We still believe strongly in the MicroFlex technology but prioritise our resources on our unique product platform for digital immunoassay.

Overall, our ground-breaking product platform for digital immunoassay has enormous potential. The platform may become the first digital, ultra-sensitive, portable POC platform for testing high-sensitivity troponin and eventually for performing many other clinical tests in large indication areas. The system is also very easily operated and has low production costs making it incredibly cost-effective, just what the market demands. Our strong team is highly motivated to do its utmost to deliver the best POC systems to healthcare providers and patients in the rapidly growing point-of-care testing market.

Lund in February 2023

Ulf Bladin, CEO Prolight Diagnostics AB (publ)



Safe point-of-care tests enable faster diagnoses

Prolight is developing a new, flexible Point-of-Care (POC) testing platform with the same sensitivity and precision as hospital laboratories so that doctors and healthcare professionals can make a correct diagnosis quickly and safely. The aim is to provide a basis for adequate treatment already when the patient is examined at, for example, an emergency department, a health centre, an ambulance, or a retirement home.

The new digital immunoassay technology was incorporated into Prolight in early 2022 through the acquisition of the British company Psyros Diagnostics (Psyros), which has developed a new, cutting-edge POC technology for digital immunoassay. Psyros currently has a highly competent team with long and broad experience in In Vitro Diagnostic (IVD) development, especially in POC tests and POC systems. The team has unique competencies and experiences vital to the Company's continued development.

Psyros' ground-breaking POC technology digitally counts individual molecules from a drop of blood. This patent-pending technique, which also offers multiplexing capability, will allow measurement of biomarkers with extremely low detection levels (femtomolar 10^{-15}) within about 10 minutes or less. To Prolight's knowledge, no other existing digital POC system is deemed capable of performing these analyses with such ease. The system consists of an easy-to-use cartridge and portable instrument. Only one drop of blood is required to perform the test.

The cutting-edge technology will first be used to develop a diagnostic POC test that measures the protein troponin with high sensitivity and accuracy, to diagnose or rule out myocardial infarction. By measuring the biomarker troponin, which is released from the heart into

the bloodstream during the acute phase of myocardial infarction, the test helps to make a rapid diagnosis. Elevated levels of the protein troponin in the blood are a sign of damage in the heart muscle cells. The protein regulates the cell's ability to contract and relax. The test places great demands on sensitivity and precision and has a substantial global sales potential.

The technology also opens up the possibility of developing new POC tests in a wide range of clinical areas that were previously only possible to carry out in specialised laboratories.

Prolight has demonstrated that its digital high-sensitivity immunoassay can measure low levels of specific proteins down to single-digit nanograms per litre (ng/L) with laboratory-grade reproducibility. These concentrations are indicative of those required to rule out myocardial infarction with highly sensitive troponin assays. We obtained these proof-of-performance results in November 2022 by measuring Thyroid Stimulating Hormone (TSH) levels in human plasma samples.

The development work will focus on continued development of the unique POC technology for digital immunoassay. This development work includes further data generation, so-called proof-of-performance, developing prototype systems for instruments and cartridges, conducting sensitivity analyses, developing a commercial system for verification and validation studies, developing cartridge manufacturing, starting a clinical validation study, and compiling regulatory documentation to begin the registration process in the US and Europe.

Vision

Prolight Diagnostics' point-of-care testing system will help healthcare providers make quick and reliable diagnoses. An early and correct diagnosis enables the healthcare system to provide effective care to the right patients. Prolight Diagnostics will offer innovative POC systems to companies with global sales organisations in relevant POC segments.

Strategy

With Prolight's POC system, the ambition is to allow caregivers to focus on implementing the proper treatment instead of spending critical time waiting for test results from a hospital laboratory. The aim is to have test results available to doctors within ten minutes.

Prolight develops innovative, flexible POC systems to achieve test results with hospital laboratory precision so physicians can make accurate diagnoses quickly and safely. The ambition is to offer a basis for adequate treatment already

when the patient is examined in, for example, an emergency department, a health centre, an ambulance, or a retirement home.

Initially, the focus will be on measuring the biomarker troponin with high sensitivity and precision, which has a substantial global sales potential. The intention is also to include more biomarkers on the Company's platform if they are deemed to be strategically and economically beneficial.

Point of Care

- an expanding global market

There is a clear and strong need for fast and accurate point of care testing. The market demands that more tests be moved out of the large hospital laboratories and closer to the patient and treating caregivers. Interest in POC testing increased significantly during the COVID-19 pandemic, which led to increased recognition of the value of rapid, simple, and effective testing close to the patient. Many companies, clinics, private individuals, politicians, and other actors now realise that this type of testing can bring significant added value to patients, healthcare, and companies. Therefore, the need for safe, precise, and high-quality POC tests is expected to continue to grow.

The global POC testing market increased strongly to around BUSD 34.6 during the pandemic year 2021 (BUSD 29.1 in 2020) and is expected to grow to around BUSD 70.9 in 2030, representing a CAGR of around 7.9 percent².

The global market for cardiac bio markers

The global market for cardiac bio markers amount-

ed to approximately BUSD 9.0 in 2021 and is expected to grow at around 9 percent per year until 2027. The estimated global market is therefore expected to reach around BUSD 14.9 by 2027³. Regarding POC tests for bio-heart markers, the market is driven by an increase in the number of people with heart disease and a growing awareness of the need for early diagnosis to provide the right patients with timely and relevant care provisions.

Trends favouring the market development of POC tests

The main drivers for the overall growth of POC testing, in addition to the COVID-19 pandemic, are expected to be increasing diagnostic needs in developing countries, growing demand for centralised laboratory testing moved to clinics closer to the patient, such as primary care and retirement homes, rapid technological development, digitalisation in healthcare, increasing investment in research and development, and an ageing population in the West.

² Global Market Insights, Point of Care Testing Market 2022-2030, juli 2022.

³ IMARC Group, Cardiac Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and forecast 2022-2027, december 2021



Cutting-edge technology

- Good conditions for developing the best and most innovative POC systems in the market

Prolight is well-positioned to develop the best and most innovative POC systems in the market for cardiac markers such as troponin and other clinical tests in several large indication areas, including tests for biomarkers not yet available in the POC market and multiplex assays.

A new ground-breaking POC technology for digital immunoassay

By acquiring Psyros, Prolight now has an entirely new cutting-edge POC technology for digital immunoassay, which can digitally count individual molecules from a drop of blood. The unique technology of the Company's digital immunoassay opens up the possibility of developing new POC tests in a wide range of clinical areas that were previously only possible to carry out in specialised laboratories. Further advantages of the digital immunoassay include its simplicity and low production costs.

Precision at the level of PCR tests, but with significantly faster response time

Today, PCR tests are recommended to detect COVID-19, but the response time is lengthy, sometimes several hours to days, depending on the system and queue times. By using the digital assay technology, it is possible to digitally count individual molecules at low levels, even for viral particles such as corona. As a result, sensitivity and accuracy can be as good or better than what PCR tests currently offer on large central laboratory instruments. The large and highly significant difference between today's PCR tests and the Company's innovative digital POC platform is that the response time can be reduced to just ten minutes or less.

May be the start of a paradigm shift in point-of-care testing, POC

This technology shift is expected to mark the beginning of a paradigm shift in POC, creating new conditions for greatly improved technologies that can provide good efficiency gains in clinical diagnostics. Some examples of possible future clinical areas are neuropathology (dementia, traumatic brain injuries), immune system dysfunction (sepsis, autoimmune diseases), and detecting viruses such as COVID-19. The unique technology behind the digital immunoassay can make it possible to test completely different biomarkers with high sensitivity and accuracy on a single POC instrument. Prolight believes that this could represent a paradigm shift in POC testing for clinical diagnostics.



Prolight has a strong patent portfolio

The patent situation for the digital immunoassay

For the digital immunoassay, Prolight's subsidiary Psyros has three patent applications filed. The first application has completed the PCT phase and is now being pursued in different territories worldwide. The second application is in the PCT phase, and the third is about to enter the PCT phase. The latest patent application was filed with the Intellectual Property Office in the UK in April 2022 and relates to an improved measurement of individual molecules. This innovation contributes to even faster testing on the Company's POC platform while simplifying the detection system, enabling lower costs for the instrument.

The patent situation for PLD MicroFlex

For PLD MicroFlex, the patent portfolio consists of four granted patents (two in the US, one in the EU, and one in Sweden), along with four patent applications, the latest of which was filed in 2020. One of the patent applications concerns how the sampling tube can be directly integrated into the test card. Another patent application concerns test cards containing an integrated centrifuge. This makes for a straightforward workflow for any clinical environment. No trained personnel are needed to pipette and centrifuge the blood sample. PLD

MicroFlex thereby creates the conditions to offer a fully automated platform for immunodiagnostics. Two of the patent applications have progressed to the national phase and are now being pursued in different territories, while the others are in the PCT phase.

About PCT and patent application processes

Patent Cooperation Treaty (PCT) is an international agreement that allows you to obtain, with a single application, in one language, a novelty search and preliminary patentability assessment conducted by one authority for approximately 150 countries. For a PCT application to lead to a patent in a particular country (or territory, such as the EU), the application must be prosecuted at the respective patent office.

During the patent application process, it is normal for the reviewing authority to ask several questions, which Prolight and the company's legal representatives spend much time answering to achieve the strongest possible patent protection. This correspondence takes different amounts of time depending on each authority's questions. It is, therefore, challenging to give an exact date for when an individual patent application can be expected to be approved.



Owners

	Holdings 2022-12-31	Votes in %
AVANZA PENSION	15 511 372	5,50
FORMUE NORD MARKEDSNEUTRAL A/S	12 802 000	4,54
BNY MELLON NA (FORMER MELLON), W9*	11 253 728	3,99
CARDEON AB (PUBL)	9 350 000	3,31
AILEEN JANE MCGETTRICK	8 290 816	2,94
JULIE RICHARDS	8 290 816	2,94
PAUL BRENDAN MONAGHAN	8 290 816	2,94
STEVEN ANDREW ROSS	8 290 816	2,94
GÜNTHER & WIKBERG HOLDING AB	4 558 693	1,62
GRYNINGSKUST FÖRVALTNING AB	3 958 693	1,40
Total, 10 largest owners	90 597 750	31,51
Other	191 671 704	68,49
Total	282 269 454	100,0

* Refers to the technology and development partner's ownership (TTP, via management structure).

The company has outstanding warrants of 95,202,981 and warrants for management and the board of 2,500,000 that can entail 81,835,742.5 shares and can thus cause dilution.

Prolight Diagnostics' share is traded on the Nordic Growth Market, NGM SME, under the name PRLD.

The group's development during quarter 4, 1 October to 31 December 2022

A group was formed on 1 March 2022 when Prolight Diagnostics AB completed the acquisition of the English subsidiary Psyros Diagnostics Ltd. The group's income statement, balance sheet and cash flow refer to the period 1 March to 31 December 2022 and quarter 4, 1 October to 31 December 2022.

INCOME

- During product development, the Prolight group has no sales and net sales.
- Other income for the period amounted to SEK 2,050,875 and mainly consisted of consulting and grant income in Psyros.

COSTS AND RESULTS

- The Prolight Group's total operating costs during the period amounted to SEK 8,857,781 and consisted primarily of external costs and personnel costs related to the development of the Group's products.
- Capitalized expenditure on development and similar work amounted to SEK 3,686,825 and refers to costs for the group's product development.

FINANCING AND CASH FLOW

- Cash flow from current operations amounted to SEK -5,436,113.
- The Prolight group's cash flow from investment activities amounted to SEK -3,901,042 and in the period consists mainly of capitalized expenditure on development of SEK 3,686,826 related to the groups' product development.
- The total cash flow for the period was - SEK -9,337 155.
- Cash and cash equivalents for the group as of 31 December 2022 were SEK 54,110,725.

EQUITY AND LIABILITIES

- Equity in the group as of 31 December 2022 amounted to SEK 204,405,038.
- Short-term receivables amounted to SEK 2,728,494 and short-term liabilities amounted to SEK 2,508,028
- The total assets as of December 31, 2022 amounted to SEK 207,913,066 and mainly consist of acquired intangible fixed assets of SEK 23,075,229 regarding new technology in Psyros Diagnostics and intangible fixed assets that relate to capitalized expenditure on development and similar work and which at the end of the period amounted to SEK 127,296,140.
- The equity ratio was 99 percent.

The group's development during the period 1 March to 31 December 2022

INCOME

- During product development, the Prolight group has no sales and net sales.
- The period's other income amounted to SEK 7,760,059 and mainly consisted of consulting and grant income in mainly Psyros.

COSTS AND RESULTS

- The Prolight Group's total operating costs during the period amounted to SEK 40,161,013 and consisted primarily of external costs and personnel costs related to the development of the Group's products.
- Capitalized expenditure on development and similar work amounted to SEK 21,860,790 and refers to costs for the group's product development.

FINANCING AND CASH FLOW

- Cash flow from current operations amounted to SEK -7,664,042.
- The Prolight Group's cash flow from investment activities amounted to SEK -24,995,389 and consists in the period of primarily capitalized expenditure on development of SEK 21,860,792
- related to the company's product development and acquisition of Psyros Diagnostics Ltd and its POC technology, SEK -2,472,112.
- New issue of shares amounted to net 46,077,571 has been carried out during the period.
- The total cash flow for the period was SEK 13,418,140.

The parent company's development during the period 1 October – 31 December 2022

INCOME

- During the time of product development, Prolight has no sales and net sales, this was also the case during the comparison period.
- Other income for the period amounted to 3,429,240 (28,652) and mainly consisted of invoiced management fee to Psyros. Exchange rate gains and distribution income from NGM.

COSTS AND RESULTS

- Prolight's total operating costs during the period amounted to 2,416,061 (1,461,120) and mainly consisted of external costs linked to the development of the company's products.
- Capitalized expenditure on development and similar work amounted to SEK 49,231 (0) and refers to costs for the company's product development.
- The financial net was SEK -22,304,593 (117,312). The financial items include a write-down of investments in subsidiaries that refer to internal receivables at Psyros Diagnostics Ltd that have been converted into shareholder contributions and amount to SEK 22,615,822.
- The result for the quarter amounted to SEK -21,242,183 (-1,315,156).

FINANCING AND CASH FLOW

- Cash flow from current operations amounted to SEK -13,627,175 (-1,534,062).
- Prolight's cash flow from investment activities amounted to SEK 990 (0).
- Neither during the period nor the comparison period have loans been taken out or amortized.
- The total cash flow for the quarter was SEK -13,626,185 (-1,534,063).
- Cash and cash equivalents as of 31 December 2022 were SEK 45,550,804 (43,885,966).

EQUITY AND LIABILITIES

- Equity as of 31 December 2022 amounted to SEK 186,256,971 (146,309,462).
- Short-term receivables amounted to SEK 3,774,485 (2,368,445) and short-term liabilities to SEK 1,471,951 (2,823,668).
- The total assets as of 31 December 2022 amounted to SEK 187,728,922. (149,133,130) and mainly consists of intangible fixed assets which at the end of the period amounted to 138,403,633 (102,878,718).
- The equity ratio was 99 percent (99).

The parent company's development during the period 1 January – 31 December 2022

INCOME

- During the time of product development, Prolight has no sales and net sales, this was also the case during the comparison period.
- Other income for the period amounted to 3,651,016 (107,540) and mainly consisted of invoiced management fee to Psyros. Exchange rate gains and distribution income from NGM.

COSTS AND RESULTS

- Prolight's total operating costs during the period amounted to SEK 24,045,907 (7,125,498) and mainly consisted of external costs related to the development of the company's products.
- Capitalized expenditure on development and similar work amounted to SEK 12,257,254 (45,498) and refers to costs for the company's product development.
- The financial net was SEK -22,305,601 (117,312). The financial items include a write-down of investments in subsidiaries that refer to internal receivables at Psyros Diagnostics Ltd that have been converted into shareholder contributions and amount to SEK 22,615,822.
- The result for the period amounted to SEK -30,443,239 (-6,855,148).

FINANCING AND CASH FLOW

- Cash flow from current operations amounted to SEK -28,387,819 (-7,195,216).
- Prolight's cash flow from investment operations amounted to SEK -16,024,914 (-45,498) and consists of capitalized development expenses linked to the company's product development, as well as the acquisition of Psyros Diagnostics Ltd and its POC technology, of SEK 19,500,000 which was financed via a new issue of shares and acquisition costs of SEK 3,767,660.
- New issue of shares net 46,077,571 have been implemented during the period.
- The total cash flow for the period was SEK 1,664,838 (-7,240,714).

*Information in parentheses refers to the comparison period of the previous year.

Other information

RISKS AND UNCERTAINTIES

Prolight Diagnostics' operations are exposed to a number of risks and uncertainty factors, which to varying extents can have a negative impact on continued operations. Both external, operational and finance-related risks can negatively affect the company in the short and long term. Prolight works continuously to inventory and manage the risks and uncertainty factors that the business is exposed to in order to limit risk exposure and any impact if a risk materializes. A detailed description of risks and risk management can be found in the Annual Report for 2021.

ACCOUNTING PRINCIPLES

This interim report has been prepared in accordance with Chapter 9 of the Annual Accounts Act. Prolight applies the Accounting Board's general advice 2012:1 (K3) when preparing the company's financial reports.

AUDITOR'S REVIEW

The quarterly report has not been subject to an auditor's review.

TRANSACTIONS WITH RELATED PARTIES

No significant transactions with related parties have been carried out during the financial year 2022 except for the company's CEO and the subsidiary's CEO. The transactions have taken place on market term.

OTHER INFORMATION

The company has outstanding warrants of 95,202,981 and warrants for management and the board of 2,500,000 can be converted to 81,835,742.5 shares and can cause dilution.

Prolight Diagnostics' share is traded on the Nordic Growth Market, NGM SME, under the name PRLD.

Income Statement, summary Group

Amount in SEK	2022 oct-dec	2022 mar-dec
Net Sales	0	0
Activated work for own account*	3 686 825	21 860 791
Other income	2 050 875	7 760 059
Operating expenses		
Other external costs	-5 902 912	30 341 858
Personnel costs	-2 880 451	-9 421 579
Depreciation	-33,453	-111,598
Other operating expenses	-40 966	-285 978
Total expenses	-8 857 781	-40 161 013
Result from financial investments		
Other interest income and similar items	311 275	311 275
Other interest expenses and similar items	-46	-1 054
Total result from financial investments	311 229	310 221
Net loss	-2 808 851	-10 229 941

*Principles for capitalization own work for own account have been taken into account in this quarterly report for the subsidiary and have been adjusted for previous reports.

Balance Sheet, summary Group

Amount in SEK	2022-12-31
ASSETS	
Fixed assets	
Acquired intangible assets	23 075 229
Capitalized expenditure on development work and similar work	127 296 140
Equipment, tools, fixtures and fittings	702 478
Total fixed assets	151 073 847
Current assets	
Other receivables	1 440 372
Tax receivables	2 695
Prepaid expenses and accrued income	1 285 427
Cash and cash equivalents	54 110 725
Total current assets	56 839 219
Total assets	207 913 066
EQUITY & CURRENT LIABILITIES	
Equity	
Share capital and other contributed capital	223 830 631
Other capital including the year's profit/loss	-18 425 593
Total equity	204 405 038
Current liabilities	
Accounts payables	994 172
Other liabilities	290 747
Accrued expenses and deferred income	1 123 109
Total current liabilities	2 508 028
Total equity and liabilities	207 913 066

Changes in shareholders equity, Group

Amount in SEK	Share capital	Other paid in capital	Other capital incl result for the period	Total share-holders equity
Shareholders equity 2022-03-01	14 910 418	138 529 465	-8 125 266	145 314 617
Issue of new shares	13 316 527	73 035 648		86 352 175
Issuance cost		-15 961 427		-15 961 427
Loss for the period			-10 229 941	-10 229 941
Foreign exchange rate adjustment			-70 386	-70 386
Shareholders equity 2022-12-31	28 226 945	195 603 686	-18 425 593	205 405 038

Cash flow from operating activities

Amount in SEK	2022 oct-dec	2022 mar-dec
Operating activities		
Profit after financial items	-2 808 851	-10 229 941
Adjustment	43 713	112 088
<i>Cashflow from operating activities before changes in working capital</i>	-2 765 138	-10 117 853
<i>Cash flow from changes in working capital</i>		
Changes in receivables	-1 122 789	4 007 682
Changes in liabilities	-1 548 186	-1 553 871
<i>Total changes in working capital</i>	-2 670 975	2 453 811
Cash flow from operating activities	-5 436 113	-7 664 042
Investeringsverksamheten		
Investment in intangible assets	-3 686 826	-21 860 792
Investment in tangible assets	-214 216	-662 485
Acquisition of company	0	-2 472 112
Cash flow from investment activities	-3 901 042	-24 995 389
Financing activities		
Share issue	0	46 077 571
Cash flow from financing activities	0	46 077 571
Cash flow for the period	-9 337 155	13 418 140
Cash and equivalents at the beginning of period	63 447 881	40 648 324
Exchange rate differences in cash	0	44 261
Cash and equivalents at the end of period	54 110 725	54 110 725

Income Statement, summary

Amount in SEK	2022 oct-dec	2021 oct-dec	2022 jan-dec	2021 jan-dec
Net Sales	0	0	0	0
Activated work for own account	49 231	0	12 257 254	45 498
Other income	3 429 240	28 652	3 651 016	107 540
Operating expenses				
Other external costs	-2 323 672	-1 327 446	-23 454 107	-6 625 166
Personnel costs	-51 422	-125 125	-274 955	-479 329
Other operating expenses	-40 966	-8 549	-316 845	-21 003
Total expenses	-2 416 061	-1 461 120	-24 045 907	-7 125 498
Result from financial investments				
Write-down of investment in subsidiary	-22 615 822	0	-22 615 822	0
Other interest income and similar items	311 275	117 312	311 275	117 312
Other interest expenses and similar items	-46	0	-1 054	0
Total result from financial investments	-22 304 593	117 312	-22 305 601	117 312
Net loss	-21 242 183	-1 315 156	-30 443 239	-6 855 148

Balance Sheet, summary

Amount in SEK	2022-12-31	2021-12-31
ASSETS		
Fixed assets		
Capitalized expenditure on development work and similar work	115 135 972	102 878 718
Participation in group companies	23 267 661	0
Total fixed assets	138 403 633	102 878 718
Current assets		
Other receivables	272 426	302 605
Tax receivables	2 695	2 695
Intercompany receivables	3 387 220	0
Prepaid expenses and accrued income	112 144	2 063 145
Cash and cash equivalents	45 550 804	43 885 966
Total current assets	49 325 289	46 254 411
Total assets	187 728 922	149 133 130
EQUITY & CURRENT LIABILITIES		
Equity		
Restricted equity	139 428 747	113 854 965
Profit or loss brought forward / Loss for the year	46 828 225	32 454 497
Total equity	186 256 971	146 309 462
Current liabilities		
Accounts payables	471 025	898 084
Accrued expenses and deferred income	1 000 926	1 925 584
Total current liabilities	1 471 951	2 823 668
Total equity and liabilities	187 728 922	149 133 130

Changes in shareholders equity

Amount in SEK	Restricted equity			Non restricted equity			Total share holders equity
	Share-capital	Statutory reserve	Reserve development cost	Share premium reserve	Profit/loss brought forward	Profit/loss for the year	
Shareholders equity 2022-01-01	14 910 418	13 047 052	85 897 495	125 482 413	-86 172 768	-6 855 148	146 309 462
Decided at AGM					-6 855 148	6 855 148	0
Issue of new shares	13 316 527			73 035 648			86 352 175
Issuance cost				-15 961 427			-15 768 927
Reserve development costs			12 257 254		-12 257 254		0
Loss for the period						-30 443 239	-30 443 239
Shareholders equity 2022-12-31	28 226 945	13 047 052	98 154 749	182 556 634	-105 285 170	-30 443 239	186 256 971

Amount in SEK	Restricted equity			Non restricted equity			Total share holders equity
	Share-capital	Statutory reserve	Reserve development cost	Share premium reserve	Profit/loss brought forward	Profit/loss for the year	
Shareholders equity 2021-01-01	14 910 418	13 047 052	85 851 998	125 482 413	-81 826 834	-4 300 437	153 164 611
Decided at AGM					-4 300 437	4 300 437	0
Reserve development costs			45 497		-45 497		0
Loss for the period						-6 855 148	-6 855 148
Shareholders equity 2021-12-31	14 910 418	13 047 052	85 897 495	125 482 413	-86 172 768	-6 855 148	146 309 462

Cash flow statement

Amount in SEK	2022 oct-dec	2021 oct-dec	2022 jan-dec	2021 jan-dec
OPERATING ACTIVITIES				
Profit after financial items	-21 242 183	-1 315 156	-30 443 239	-6 855 148
Adjustment	0	-2 695	0	-2 695
<i>Cashflow from operating activities before changes in working capital</i>	-21 242 183	-1 317 851	-30 443 239	-6 857 843
<i>Cash flow from changes in working capital</i>				
Changes in receivables	7 686 209	-1 913 238	-1 406 040	-1 979 582
Changes in liabilities	-71 201	1 697 026	3 461 460	1 642 208
<i>Total changes in working capital</i>	7 615 008	-216 212	2 055 420	-337 374
Cash flow from operating activities	-13 627 175	-1 534 063	-28 387 819	-7 195 216
INVESTMENT ACTIVITIES				
Investment in intangible assets	-49 231	0	-12 257 254	-45 498
Acquisition in group companies	50 221	0	-3 767 661	0
Cash flow from investment activities	990	0	-16 024 915	-45 498
FINANCING ACTIVITIES				
Share issue	0	0	46 077 571	0
Cash flow from financing activities	0	0	46 077 571	0
Cash flow for the period	-13 626 185	-1 534 063	1 664 838	-7 240 714
Cash and equivalents at the beginning of period	59 176 989	45 420 029	43 885 966	51 126 680
Cash and equivalents at the end of period	45 550 804	43 885 966	45 550 804	43 885 966

Key ratios

	2022 oct-dec	2021 oct-dec	2022 jan-dec	2021 jan-dec
Net Sales, MSEK	0	0	0	0
Cash and equivalents, MSEK	45,6	51,1	45,6	43,9
Equity ratio, %	99	99	99	99
Quick asset ratio, %	3 348	1 638	3 348	1 638
Number of shares in the beginning of period	277 470 338	149 104 183	149 104 183	149 104 183
Average number of shares in the period	279 123 367	149 104 183	244 898 561	149 104 183
Number of shares in the end of period	282 269 454	149 104 183	282 269 454	149 104 183
Profit/Loss, MSEK	-21,2	-1,3	-30,4	-6,9
Earnings per share, SEK	-0,08	-0,01	0,11	-0,05
Earnings per share after dilutions, SEK	-0,08	-0,01	-0,11	-0,05

Not 1 – Acquisition

On March 1, 2022, Prolight Diagnostics AB acquired 100% of the shares in Psyros Diagnostics Ltd.

Fair value of assets acquired and liabilities assumed	
Intangible assets	23 116 017
Tangible fixed assets	148 049
Current assets	5 592 430
Current liabilities	-5 588 835
Total fair value acquired net assets	23 267 661
Of which net assets attributable to non-controlling interests	0
Net assets attributable to the parent company's shareholders	23 267 661

From the acquisition date, Psyros Diagnostics Ltd. contributed SEK 7,496,263 in other income and SEK -10,150 in operating profit and excluding capitalized expenditures of SEK 12,135,468.



Prolight Diagnostics, together with the subsidiary Psyros Diagnostics and technology partners, develops innovative and flexible near-patient testing systems, Point-of-Care Testing (POCT), which is IT based on patented technology. POC tests are performed outside the traditional hospital laboratory with small mobile instruments in health centres, nursing homes, emergency departments, intensive care units, and other settings, enabling testing close to the patient and with rapid test results. With this technology, health care providers will be able to sort out patients in need of rapid treatment from patients that, for example, are not having a heart attack. The sales value in the POCT area amounted to USD 34.6 billion in 2021 and is growing strongly.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

For further information:
info@prolightdiagnostics.se
+46 (0)73 582 39 87
www.prolightdiagnostics.se

Prolight 
Diagnostics